图片二：天大药业产品图 在近日举行的"2025腾冲科学家论坛"上，天大集团董事长方文权接受云南媒体联合采访，首次系统阐释集团在滇 发展新蓝图。基于过去三十年累计超十亿元的投资根基，集团正式宣布启动"医药健康+精细磷化工"双轮驱动战 略，标志着其在滇产业布局进入协同发力、升级发展的新阶段。 图片一：2025腾冲科学家论坛"、"投资云南"招商大会 作为双轮战略的核心引擎之一，旗下上市平台天大药业(00455.HK)将全面深化在云南的医药健康产业布局。云南 作为"中药材之乡"，其独特的生物资源将成为天大药业发展的关键支撑。公司宣布，将依托自主研发的"天大标 准"质量管理体系，构建从中药材源头到消费终端的产品全生命周期品质管控，加大对云南道地药材产业的系统性 投资。 目前，天大药业的产品矩阵已覆盖心脑血管、儿科、呼吸系统、抗感染及抗肿瘤等关键治疗领域，并培育了"和 谷"、"托康"等市场认可的品牌。未来，公司将通过"天大馆"及"云上天大馆"线上线下（300959）融合的中医健康 服务平台，推动源自云南的优质产品与服务走向全国乃至全球市场。 与此同时，双轮中的另一核心——精细磷化工产业也将同步发力。集团将以寻甸磷矿项目为 ...

Group 1 - The core viewpoint of the news highlights the recent performance of Tian Da Pharmaceutical, which saw a stock price increase of 8.57% despite a decline in overall revenue and profit [1][2] - Tian Da Pharmaceutical's cumulative increase over the past month is 2.94%, and 3.55% year-to-date, underperforming the Hang Seng Index by 25.45% [2] - Financial data shows that as of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99%, and a net profit attributable to shareholders of -56.83 million yuan, a decrease of 154.07% [2] Group 2 - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The pharmaceutical and biotechnology industry has an average price-to-earnings (P/E) ratio of -2.05 times, with a median of 1.44 times; Tian Da Pharmaceutical's P/E ratio stands at -6.13 times, ranking 136th in the industry [3] - The company focuses on developing traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical sector [4] Group 3 - Tian Da Pharmaceutical is committed to building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - The company utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and aims to expand its market presence both domestically and internationally [4] - The company has established marketing centers in Shenzhen and Zhuhai, and is gradually setting up branches in the US and Europe to support its international sales and brand development [4] Group 4 - A significant event reminder includes the disclosure of the mid-year report for the fiscal year 2025 on August 28, 2025 [5]

Company Overview - Tian Da Pharmaceutical Co., Ltd. focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical and healthcare sectors [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of Chinese medicine clinic called "Tian Da Clinic" [4] - Tian Da Pharmaceutical utilizes internet technology, big data, and artificial intelligence to integrate online and offline services, providing comprehensive healthcare services [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% year-on-year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.44 times, with a median of 4.53 times [3] - Tian Da Pharmaceutical has a P/E ratio of -5.26 times, ranking 125th in the industry [3] - Comparatively, other companies in the sector have P/E ratios ranging from 0.72 times to 4.28 times [3] Recent Stock Performance - As of May 9, the Hang Seng Index increased by 0.4%, closing at 22,867.74 points [1] - Tian Da Pharmaceutical's stock price was 0.162 HKD per share, reflecting an increase of 8.0% with a trading volume of 2,000 shares and a turnover of 326 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.71%, and a year-to-date decline of 11.24%, underperforming the Hang Seng Index's increase of 13.54% [2]